Skip to main content

Akero Therapeutics shares plunge on liver disease treatment’s mixed results

Company's lead product candidate shows some benefit for patients with cirrhosis due to fatty liver disease
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.